Egypt - English - EDA (Egyptian Drug Authority)

searle-canada - tablet - 1.5 mg

Egypt - English - EDA (Egyptian Drug Authority)

searle-canada - tablet - 5 mg

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - arthrotec is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2)] . arthrotec is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium/misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions (5.7, 5.9)] known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium/misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids

United States - English - NLM (National Library of Medicine)

g.d. searle llc division of pfizer inc - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 80 mg - calan tablets are indicated for the treatment of the following: - angina at rest including: — vasospastic (prinzmetal's variant) angina — unstable (crescendo, pre-infarction) angina - chronic stable angina (classic effort-associated angina) - in association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see warnings: accessory bypass tract ) - prophylaxis of repetitive paroxysmal supraventricular tachycardia calan is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control,

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 36 microgram; norethisterone, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; magnesium stearate - indications as at 31 august 1998 : contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 500 microgram; ethinylestradiol, quantity: 36 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose; sunset yellow fcf; lactose monohydrate - 31 august 1998 : contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; indigo carmine; acacia; magnesium stearate; calcium hydrogen phosphate dihydrate - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. 2 short .term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

United States - English - NLM (National Library of Medicine)

g.d. searle llc - valdecoxib (unii: 2919279q3w) (valdecoxib - unii:2919279q3w) - tablet, film coated - 10 mg - bextra tablets are indicated: - for relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis. - for the treatment of primary dysmenorrhea. bextra should not be given to patients who have demonstrated allergic-type reactions to sulfonamides. bextra tablets are contraindicated in patients with known hypersensitivity to valdecoxib. bextra should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids are possible in such patients (see warnings — anaphylactoid reactions, and precautions — preexisting asthma). bextra is contraindicated for the treatment of post-operative pain immediately following coronary artery bypass graft (cabg) surgery and should not be used in this setting. (see clinical studies — safety studies).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 1 mg; ethinylestradiol, quantity: 36 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; magnesium stearate - indications as at 31 august 1998 : contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 36 microgram; norethisterone, quantity: 500 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; sunset yellow fcf; magnesium stearate; microcrystalline cellulose; lactose - indications as at 31 august 1998 : contraception